Sacituzumab Tirumotecan With or Without Pembrolizumab for Ovarian Clear Cell Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug (sacituzumab tirumotecan) with or without pembrolizumab for ovarian clear cell cancer that has returned or spread. It's for people who have already had chemotherapy and one type of immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of ovarian cancer called 'pure clear cell' (not mixed with other types).
- You must have had at least one round of chemotherapy that included platinum and taxane drugs.
- You must have had exactly one previous treatment with an immunotherapy (checkpoint inhibitor) drug.
- You cannot have cancer that has spread to the brain.
- You must be able to do most daily activities without help (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy called Sacituzumab for people with a rare type of ovarian cancer (clear cell carcinoma) whose cancer worsened after immunotherapy. The drug is designed to deliver chemotherapy directly to cancer cells, and researchers want to see if it can help when other treatments stop working.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This trial tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) for women whose ovarian cancer stopped responding to platinum chemotherapy. The goal is to see if the combination helps shrink or slow the cancer.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, given before surgery for triple-negative breast cancer (a type of breast cancer that lacks three common markers). The study aims to see if this treatment can shrink tumors and improve outcomes.
This trial tests a new cancer drug called sacituzumab tirumotecan (a targeted antibody-drug) in patients with adenoid cystic carcinoma or papillary thyroid cancer that has spread or cannot be surgically removed. The drug is designed to find and attack cancer cells while minimizing harm to healthy cells.
Hear when a new Ovarian Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.